A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

Summary

The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM). The study will also evaluate if LY3532226 helped participants to recover from insulin-induced low blood sugar condition compared to placebo. The study will last approximately 16 weeks excluding screening period.

Timeline

Start

2023-06-12

Primary completion

2024-02-21

Completion

2024-02-21

Drugs

Indications